Abstract
The effectiveness of buserelin, a luteinizing hormone-releasing hormone agonist, was tested in 28 patients with Stages C or D adenocarcinoma of the prostate. Of 24 evaluable patients, there were 13 partial responses (54%) by National Prostatic Cancer Project criteria, median duration greater than 6 months. Nine patients had stable disease (38%), median duration greater than 5 months, and only 2 patients progressed. Performance status improved in 38%, patient-scored pain improved in 46%, and quality of life improved in 57%. Symptoms occurring during treatment consisted of hot flashes, loss of libido, and impotence. A flare of symptoms was observed in only one patient, despite a transient 25% increase in testosterone in 36% of patients. Buserelin is an effective treatment for inducing frequent and meaningful remissions in advanced prostatic cancer.
Original language | English (US) |
---|---|
Pages (from-to) | 2416-2419 |
Number of pages | 4 |
Journal | Cancer |
Volume | 56 |
Issue number | 10 |
DOIs | |
State | Published - Nov 15 1985 |
ASJC Scopus subject areas
- Oncology
- Cancer Research